Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.46 |
| ▸ | VDR | P11473 | 2/20 | 0.44 |
| ▸ | RORC | P51449 | 5/20 | 0.41 |
| ▸ | RORA | P35398 | 4/20 | 0.41 |
| ▸ | RORB | Q92753 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1092812 | 0.83 | PGR (0.46) | PGRNR1H3NR1H2RORCRORA | |
| SCHEMBL542643 | 0.82 | NR1H2 (0.48) | PGRNR1H3NR1H2RORCRORA | |
| SCHEMBL4886580 | 0.81 | VDR (0.63) | PGRNR1H3NR1H2VDRRORC | |
| SCHEMBL542318 | 0.81 | NR1H2 (0.46) | PGRNR1H3NR1H2RORCRORA | |
| SCHEMBL1512343 | 0.81 | NR1H2 (0.46) | PGRNR1H3NR1H2RORCRORA | |
| SCHEMBL2639809 | 0.79 | VDR (0.77) | PGRNR1H3NR1H2VDRRORC | |
| SCHEMBL16956734 | 0.78 | VDR (0.44) | PGRVDR | |
| SCHEMBL1512743 | 0.77 | PGR (0.46) | PGRNR1H3NR1H2RORCRORA | |
| SCHEMBL4884684 | 0.77 | VDR (0.55) | PGRNR1H3NR1H2VDRRORC | |
| SCHEMBL542360 | 0.74 | NR1H3 (0.51) | PGRNR1H3NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108939-B2 | (1, 1, 1,3,3,3-hexafluoro-2 hydroxypropan-2-yl) phenyl derivative, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis | MERCK SHARP & DOHME B.V. (NL) | 2015-08-18 | — | — | US | disclosed |
| EP-2493855-B1 | (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis | MERCK SHARP & DOHME (NL) | 2014-02-26 | — | — | EP | disclosed |
| US-8357679-B2 | Hexafluoroisopropanol derivatives | MSD OSS B.V. (NL) | 2013-01-22 | — | — | US | disclosed |
| US-20120238574-A1 | (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS | N.V. ORGANON (NL) | 2012-09-20 | — | — | US | disclosed |
| EP-2297118-B1 | N- (1, 1, 1, 3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) BENZYL-N' -ARYLCARBONYLPIPERAZ INE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-10-05 | — | — | EP | disclosed |
| US-20100029621-A1 | HEXAFLUOROISOPROPANOL DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029621-A1 | HEXAFLUOROISOPROPANOL DERIVATIVES | FFAR2, FFAR3, FFAR1 | PGR 2851/4885NR1H3 9/4885NR1H2 10/4885 |
| US-20120238574-A1 | (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS | TGFB1, FPR1, TGFB2 | PGR 2620/4885NR1H3 41/4885NR1H2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.